GD2 and GD3 synthase: novel drug targets for cancer therapy. uri icon

abstract

  • Our recent study suggests that targeting GD3 synthase (also known as ST8SIA1)-the rate-limiting enzyme in biosynthesis of the breast cancer stem cell marker GD2-abrogates metastasis and depletes the cancer stem cell populations within a tumor, thus providing an effective therapeutic strategy against metastatic breast cancers.

published proceedings

  • Mol Cell Oncol

altmetric score

  • 0.25

author list (cited authors)

  • Sphyris, N., Sarkar, T. R., Battula, V. L., Andreeff, M., & Mani, S. A.

citation count

  • 6

complete list of authors

  • Sphyris, Nathalie||Sarkar, Tapasree Roy||Battula, Venkata L||Andreeff, Michael||Mani, Sendurai A

publication date

  • July 2015